Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases.
Stock is 
Press Release
 View printer-friendly version << Back

Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015

CAMBRIDGE, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company is scheduled to present at the Canaccord Genuity 35th Annual Growth Conference in Boston on Wednesday, August 12, 2015 at 8:30 a.m. EDT.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios Pharmaceuticals

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at

CONTACT: Renee Leck, Senior Manager,
         Investor Relations and Public Relations

Agios Pharmaceuticals logo

Agios Pharmaceuticals